---
title: "Medpace Holdings, Inc. (MEDP.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/MEDP.US.md"
symbol: "MEDP.US"
name: "Medpace Holdings, Inc."
industry: "Life Sciences Tools and Services"
datetime: "2026-05-19T16:10:11.409Z"
locales:
  - [en](https://longbridge.com/en/quote/MEDP.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/MEDP.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/MEDP.US.md)
---

# Medpace Holdings, Inc. (MEDP.US)

## Company Overview

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.

| Item | Detail |
|------|--------|
| Industry | Life Sciences Tools and Services |
| Exchange | US Market |
| Website | [www.medpace.com](https://www.medpace.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:13.000Z

**Overall: B (0.30)**

**Industry**: Life Sciences Tools and Services

| Metric | Value |
|--------|-------|
| Industry Ranking | 6 / 59 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 24.19% |  |
| Net Profit YoY | 10.57% |  |
| P/B Ratio | 20.08 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 12014204371.63 |  |
| Revenue | 2678268000.00 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 77.25% | A |
| Profit Margin | 17.19% | A |
| Gross Margin | 71.94% | A |
| Revenue YoY | 24.19% | A |
| Net Profit YoY | 10.57% | C |
| Total Assets YoY | 12.24% | B |
| Net Assets YoY | 0.79% | C |
| Cash Flow Margin | 160.55% | B |
| OCF YoY | 24.19% | A |
| Turnover | 1.33 | A |
| Gearing Ratio | 71.91% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Medpace Holdings, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "24.19%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "10.57%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "20.08",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "12014204371.63",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "2678268000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "77.25%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "17.19%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "71.94%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "24.19%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "10.57%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "12.24%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "0.79%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "160.55%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "24.19%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "1.33",
          "rating": "A"
        },
        {
          "name": "Gearing Ratio",
          "value": "71.91%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 26.10 | 11/59 | 37.21 | 31.73 | 25.89 |
| PB | 20.08 | 52/59 | 73.89 | 53.87 | 19.93 |
| PS (TTM) | 4.49 | 36/59 | 6.85 | 5.83 | 4.45 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | ChromaDex (CDXC.US) | A | A | A | B | A | A |
| 02 | Agilent Tech (A.US) | A | C | B | C | C | B |
| 03 | West Pharmaceutical (WST.US) | B | B | B | B | B | B |
| 04 | Illumina (ILMN.US) | A | C | B | D | C | B |
| 05 | WuXi Biologics (WXXWY.US) | B | B | C | A | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-14T04:00:00.000Z

Total Analysts: **13**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 3 | 23% |
| Overweight | 1 | 8% |
| Hold | 8 | 62% |
| Underweight | 1 | 8% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 421.26 |
| Highest Target | 495.00 |
| Lowest Target | 329.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/MEDP.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/MEDP.US/norm.md)
- [Related News](https://longbridge.com/en/quote/MEDP.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/MEDP.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**